Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
Sponsor: University Health Network, Toronto
Summary
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Official title: From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
360
Start Date
2021-07-06
Completion Date
2027-03-30
Last Updated
2024-12-06
Healthy Volunteers
No
Conditions
Locations (3)
Michael Garron Hospital
Toronto, Ontario, Canada
St. Joseph's Health Centre
Toronto, Ontario, Canada
University Health Network
Toronto, Ontario, Canada